BRAF and lung carcinoma: Furthermore, due to the extremely low incidence of dMMR/MSI-H in lung cancer, especially in patients with BRAF V600E mutations, evidence supporting the predictive value of dMMR/MSI-H for immunotherapy in this population is limited (34, 35).